May 13, 2020 / 4:05 PM / 3 months ago

BRIEF-Novo Nordisk Says Semaglutide 2.4 Mg Demonstrates Superior, Sustained Weight Loss Versus Placebo & In Addition 17.4% Weight Loss After 68 Weeks In Step 4 Trial

May 13 (Reuters) - Novo Nordisk A/S:

* NOVO NORDISK - ANNOUNCED HEADLINE RESULTS FROM STEP 4, FIRST COMPLETED PHASE 3A TRIAL IN STEP PROGRAMME

* NOVO NORDISK- SEMAGLUTIDE 2.4 MG DEMONSTRATES SUPERIOR, SUSTAINED WEIGHT LOSS VERSUS PLACEBO&IN ADDITION 17.4% WEIGHT LOSS AFTER 68 WEEKS IN STEP 4 TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below